Pasar al contenido principal

BUSQUEDA DE BIOMARCADORES Y NUEVAS DIANAS PARA UNA TERAPIA PERSONALIZADA EN LA ESCLEROSIS MULTIPLE

PI18/00572

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2018
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INVESTIGACION BIOMEDICA HOSPITAL RAMON Y CAJAL
Centro realización INSTITUTO RAMON Y CAJAL DE INVESTIGACION SANITARIA (IRYCIS)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genomic Multiple Sclerosis Risk Variants Modulate the Expression of the ANKRD55 - IL6ST Gene Region in Immature Dendritic Cells

  • Mena, Jorge|||0009-0001-4524-205X
  • Alloza, Iraide
  • Tulloch Navarro, Raquel
  • Aldekoa, Ane
  • Díez García, Javier
  • Villanueva Etxebarria, Ane
  • Lindskog, Cecilia
  • Antigüedad, Alfredo
  • Boyero, Sabas|||0000-0003-0383-0256
  • Mendibe-Bilbao, María del Mar
  • Álvarez de Arcaya, Amaya
  • Sánchez Menoyo, José Luis|||0000-0003-2634-8294
  • Midaglia, Luciana|||0000-0001-7981-2228
  • Villarrubia, Noelia
  • Malhotra, Sunny|||0000-0003-1112-7739
  • Montalban, Xavier|||0000-0002-0098-9918
  • Villar, Luisa M.|||0000-0002-9067-3668
  • Comabella López, Manuel|||0000-0002-2373-6657
  • Vandenbroeck, Koen|||0000-0002-6967-6485
Intronic single-nucleotide polymorphisms (SNPs) in the ANKRD55 gene are associated with the risk for multiple sclerosis (MS) and rheumatoid arthritis by genome-wide association studies (GWAS). The risk alleles have been linked to higher expression levels of ANKRD55 and the neighboring IL6ST (gp130) gene in CD4 + T lymphocytes of healthy controls. The biological function of ANKRD55, its role in the immune system, and cellular sources of expression other than lymphocytes remain uncharacterized. Here, we show that monocytes gain capacity to express ANKRD55 during differentiation in immature monocyte-derived dendritic cells (moDCs) in the presence of interleukin (IL)-4/granulocyte-macrophage colony-stimulating factor (GM-CSF). ANKRD55 expression levels are further enhanced by retinoic acid agonist AM580 but downregulated following maturation with interferon (IFN)-γ and lipopolysaccharide (LPS). ANKRD55 was detected in the nucleus of moDC in nuclear speckles. We also analyzed the adjacent IL6ST, IL31RA, and SLC38A9 genes. Of note, in healthy controls, MS risk SNP genotype influenced ANKRD55 and IL6ST expression in immature moDC in opposite directions to that in CD4 + T cells. This effect was stronger for a partially correlated SNP, rs13186299, that is located, similar to the main MS risk SNPs, in an ANKRD55 intron. Upon analysis in MS patients, the main GWAS MS risk SNP rs7731626 was associated with ANKRD55 expression levels in CD4 + T cells. MoDC-specific ANKRD55 and IL6ST mRNA levels showed significant differences according to the clinical form of the disease, but, in contrast to healthy controls, were not influenced by genotype. We also measured serum sgp130 levels, which were found to be higher in homozygotes of the protective allele of rs7731626. Our study characterizes ANKRD55 expression in moDC and indicates monocyte-to-dendritic cell (Mo-DC) differentiation as a process potentially influenced by MS risk SNPs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab

  • Toboso, Inmaculada
  • Tejeda-Velarde, Amalia
  • Alvarez-Lafuente, Roberto|||0000-0002-3132-1486
  • Arroyo, Rafael
  • Hegen, Harald
  • Deisenhammer, Florian|||0000-0003-4541-8841
  • Sainz De La Maza, Susana
  • Alvarez-Cermeño, José C.|||0000-0002-1345-2837
  • Izquierdo, Guillermo|||0000-0002-6340-5609
  • Paramo, Dolores
  • Oliva, Pedro
  • Casanova, Bonaventura|||0000-0003-3806-925X
  • Agüera-Morales, Eduardo|||0000-0002-8604-2054
  • Franciotta, Diego
  • Gastaldi, Matteo
  • Fernández Fernández, Óscar|||0000-0003-3696-789X
  • Urbaneja, Patricia
  • García Domínguez, José Manuel
  • Romero, Fernando
  • Laroni, Alicia
  • Uccelli, Antonio
  • Perez-Sempere, Angel|||0000-0002-0195-2834
  • Saiz, Albert|||0000-0002-5793-8791
  • Blanco Morgado, Yolanda|||0000-0002-1834-0498
  • Galimberti, Daniela|||0000-0002-9284-5953
  • Scarpini, Elio|||0000-0002-6395-2119
  • Espejo, Carmen|||0000-0001-9949-5901
  • Montalban, Xavier|||0000-0002-0098-9918
  • Rasche, Ludwig
  • Paul, Friedemann|||0000-0002-6378-0070
  • González, Inés
  • Álvarez, Elena
  • Ramo-Tello, Cristina|||0000-0001-8643-5053
  • Caminero, Ana B.
  • Aladro, Yolanda|||0000-0001-9459-5452
  • Calles, Carmen
  • Eguía, Pablo
  • Belenguer Benavides, Antonio|||0000-0003-2763-8218
  • Ramió-Torrentà, Lluís|||0000-0002-6999-1004
  • Quintana, Ester|||0000-0001-8885-1931
  • Martínez-Rodríguez, José E.
  • Oterino, Agustín|||0000-0002-7457-9129
  • López de Silanes, Carlos
  • Casanova, Luis I.
  • Landete Pascual, Lamberto
  • Frederiksen, Jette
  • Bsteh, Gabriel
  • Mulero, Patricia|||0000-0001-8716-8997
  • Comabella López, Manuel|||0000-0002-2373-6657
  • Hernández, Miguel A.
  • Espiño, Mercedes
  • Prieto, José M.
  • Pérez, Domingo
  • Otano-Martínez, María A.
  • Padilla, Francisco
  • García Merino, Juan Antonio
  • Navarro Canto, Laura
  • Muriel, Alfonso|||0000-0002-4805-4011
  • Frossard, Lucienne Costa
  • Villar, Luisa M.|||0000-0002-9067-3668
Overview: We assessed the role of age and disease activity as new factors contributing to establish the risk of progressive multifocal leucoencephalopathy in multiple sclerosis patients treated with natalizumab in 36 University Hospitals in Europe. We performed the study in 1,307 multiple sclerosis patients (70.8% anti-John Cunninghan virus positive antibodies) treated with natalizumab for a median time of 3.28 years. Epidemiological, clinical, and laboratory variables were collected. Lipid-specific IgM oligoclonal band status was available in 277 patients. Factors associated with progressive multifocal leucoencephalopathy onset were explored by uni- and multivariate logistic regression. Results: Thirty-five patients developed progressive multifocal leucoencephalopathy. The multivariate analysis identified anti-John Cunninghan virus antibody indices and relapse rate as the best predictors for the onset of this serious opportunistic infection in the whole cohort. They allowed to stratify progressive multifocal leucoencephalopathy risk before natalizumab initiation in individual patients [area under the curve (AUC) = 0.85]. The risk ranged from <1/3,300 in patients with anti-John Cunninghan virus antibody indices <0.9 and relapse rate.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab

  • Walo-Delgado, Paulette Esperanza
  • Monreal, Enric|||0000-0003-3293-0125
  • Medina, Silvia|||0000-0002-6051-173X
  • Quintana, Ester|||0000-0001-8885-1931
  • Sainz de la Maza, Susana|||0000-0001-8605-0049
  • Fernández Velasco, José Ignacio|||0000-0001-9148-671X
  • Lapuente, Paloma
  • Comabella López, Manuel|||0000-0002-2373-6657
  • Ramió-Torrentà, Lluís|||0000-0002-6999-1004
  • Montalban, Xavier|||0000-0002-0098-9918
  • Midaglia, Luciana|||0000-0001-7981-2228
  • Villarrubia, Noelia
  • Carrasco-Sayalero, Angela
  • Rodríguez-Martín, Eulalia
  • Roldán, Ernesto
  • Meca-Lallana, Jose Eustasio|||0000-0001-5050-9890
  • Alvarez-Lafuente, Roberto|||0000-0002-3132-1486
  • Masjuan, Jaime|||0000-0003-1329-0943
  • Costa-Frossard, Lucienne|||0000-0002-6512-4413
  • Villar, Luisa M|||0000-0002-9067-3668
UDHEBRON, To explore if baseline blood lymphocyte profile could identify relapsing remitting multiple sclerosis (RRMS) patients at higher risk of developing secondary autoimmune adverse events (AIAEs) after alemtuzumab treatment. Multicenter prospective study including 57 RRMS patients treated with alemtuzumab followed for 3.25 [3.5-4.21] years, (median [interquartile range]). Blood samples were collected at baseline, and leukocyte subsets determined by flow cytometry. We had additional samples one year after the first cycle of alemtuzumab treatment in 39 cases. Twenty-two patients (38.6%) developed AIAEs during follow-up. They had higher B-cell percentages at baseline (p=0.0014), being differences mainly due to plasmablasts/plasma cells (PB/PC, p=0.0011). Those with no AIAEs had higher percentages of CD4+ T cells (p=0.013), mainly due to terminally differentiated (TD) (p=0.034) and effector memory (EM) (p=0.031) phenotypes. AIAEs- patients also showed higher values of TNF-alpha-producing CD8+ T cells (p=0.029). The percentage of PB/PC was the best variable to differentiate both groups of patients. Baseline values >0.10% closely associated with higher AIAE risk (Odds ratio [OR]: 5.91, 95% CI: 1.83-19.10, p=0.004). When excluding the 12 patients with natalizumab, which decreases blood PB/PC percentages, being the last treatment before alemtuzumab, baseline PB/PC >0.1% even predicted more accurately the risk of AIAEs (OR: 11.67, 95% CI: 2.62-51.89, p=0.0007). The AIAEs+ group continued having high percentages of PB/PC after a year of alemtuzumab treatment (p=0.0058). A PB/PC percentage <0.1% at baseline identifies MS patients at low risk of secondary autoimmunity during alemtuzumab treatment.​